Prothena Plc Net Income From Continuing Ops Over Time
| PRTA Stock | USD 14.05 0.12 0.86% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Prothena Plc Performance and Prothena Plc Correlation. Prothena |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share 2.482 | Quarterly Revenue Growth (0.99) | Return On Assets (0.16) | Return On Equity (0.23) |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Prothena plc and related stocks such as Scpharmaceuticals, Milestone Pharmaceuticals, and Oncolytics Biotech Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCPH | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (24.4 M) | (23.8 M) | (29.4 M) | (33 M) | (32.2 M) | (28 M) | (36.8 M) | (50.2 M) | (47.7 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (58.4 M) | (59.3 M) | (62.2 M) |
| ONCY | 0.0 | 0.0 | 0.0 | 0.0 | (16 M) | (5.2 M) | (15.1 M) | (15.6 M) | (17 M) | (33.1 M) | (22.5 M) | (26.3 M) | (24.8 M) | (32.4 M) | (30.7 M) |
| MCRB | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (141.3 M) | (148.3 M) |
| ETNB | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (57.4 M) | (49.5 M) | (90.1 M) | (102 M) | (126.6 M) | (120.2 M) |
| MDGL | (47.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.5 M) | (33 M) | (83.9 M) | (202.3 M) | (242.1 M) | (295.4 M) | (373.6 M) | (354.9 M) |
| PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (631 K) | (41.5 M) | (97.3 M) | (123.3 M) | (155.3 M) | (147.5 M) |
| ACLX | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (32.1 M) | (65 M) | (188.7 M) | (129.5 M) | (136 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (32.3 M) | (52.2 M) | (85.8 M) | (101.1 M) | (103.4 M) | (98.2 M) |
| VTYX | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (28.2 M) | (83.7 M) | (108.4 M) | (181.4 M) | (172.4 M) |
| IMCR | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (103.9 M) | (74.1 M) | (131.5 M) | (41.2 M) | (54.1 M) | (56.8 M) |
| PCVX | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (50.3 M) | (89.2 M) | (100.1 M) | (223.5 M) | (402.3 M) | (382.2 M) |
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (81.9 M) | (114 M) | (108.3 M) |
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (21.7 M) | (59.5 M) | (65.6 M) | 109.2 M | (155.1 M) | (147.3 M) |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (64.9 M) | (103.2 M) | (161.9 M) | (161.4 M) | (157.9 M) | 183.4 M | (6.7 M) | (7 M) |
| VRDN | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.6 M) | (130.1 M) | (216.7 M) | (205.8 M) |
Prothena plc and related stocks such as Scpharmaceuticals, Milestone Pharmaceuticals, and Oncolytics Biotech Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Prothena plc | PRTA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Ireland |
| Exchange | NASDAQ Exchange |
USD 14.05
Check out Prothena Plc Performance and Prothena Plc Correlation. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Prothena Plc technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.